Background Individuals with cancer, particularly those who are receiving systemic anticancer
treatments, have been postulated to be at increased risk of mortality from COVID-19. This …

Background Patients with cancer are purported to have poor COVID-19 outcomes. However,
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …

Immune checkpoint inhibitor (ICI) therapy has revolutionised the treatment of various cancer
types. ICIs reinstate T-cell function to elicit an anti-cancer immune response. The resulting …

Importance Large cohorts of patients with active cancers and COVID-19 infection are needed
to provide evidence of the association of recent cancer treatment and cancer type with …

Delayed‐type, T cell–mediated, drug hypersensitivity reactions are a serious unwanted
manifestation of drug exposure that develops in a small percentage of the human population. …

Immunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors)
significantly improves survival in a number of cancers. Treatment can be limited by immune-…

… Anna Olsson-Brown, research fellow3 … Anna Olsson-Brown, research fellow at the
University of Liverpool, engaged in quality improvement in her F1 year, and has since …

Background & Aims The pathogenesis of immune checkpoint inhibitor (ICI)–colitis remains
incompletely understood. We sought to identify key cellular drivers of ICI-colitis and their …

In December, 2019, several cases of acute respiratory syndrome in Hubei province, China
were identified; these were the first described cases of COVID-19. The causative virus, SARS-…

Background Immune checkpoint inhibitors (ICI) improve survival but cause immune-related
adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/…